Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20569113 | 1.00 | CYP1A2 (0.39) | CYP1A2CYP2A6PDPK1GPR3PLAU | |
| SCHEMBL20154342 | 0.77 | RAB9A (0.40) | CYP1A2GPR3NPC1RAB9A | |
| SCHEMBL21271494 | 0.77 | RAB9A (0.40) | CYP1A2GPR3NPC1RAB9A | |
| SCHEMBL12315085 | 0.75 | NR4A1 (0.47) | GPR3NPC1RAB9A | |
| SCHEMBL22230368 | 0.75 | NR4A1 (0.47) | GPR3NPC1RAB9A | |
| SCHEMBL29662301 | 0.75 | NR4A1 (0.47) | GPR3NPC1RAB9A | |
| SCHEMBL29504028 | 0.75 | NR4A1 (0.47) | GPR3NPC1RAB9A | |
| SCHEMBL22230365 | 0.75 | NR4A1 (0.47) | GPR3NPC1RAB9A | |
| SCHEMBL30708147 | 0.75 | NR4A1 (0.47) | GPR3NPC1RAB9A | |
| SCHEMBL16746574 | 0.75 | NR4A1 (0.47) | GPR3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371562-A2 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-3630749-B1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11161839-B2 | 2-quinolone derived inhibitors of BCL6 | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210206756-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-08 | — | — | US | disclosed |
| EP-3630749-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215798-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161839-B2 | 2-quinolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | CYP1A2 1716/4885CYP2A6 1069/4885PDPK1 2098/4885 |
| US-20210206756-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | CYP1A2 1716/4885CYP2A6 1069/4885PDPK1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.